Cargando…

Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus

BACKGROUND: Optogenetic tools allow precise manipulation of neuronal activity via genetically encoded light-sensitive proteins. Currently available optogenetic inhibitors are not suitable for prolonged use due to short-lasting photocurrents, tissue heating, and unintended changes in ion distribution...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleis, P., Paschen, E., Häussler, U., Bernal Sierra, Y. A., Haas, C. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760681/
https://www.ncbi.nlm.nih.gov/pubmed/35031048
http://dx.doi.org/10.1186/s12915-021-01210-1
_version_ 1784633373862395904
author Kleis, P.
Paschen, E.
Häussler, U.
Bernal Sierra, Y. A.
Haas, C. A.
author_facet Kleis, P.
Paschen, E.
Häussler, U.
Bernal Sierra, Y. A.
Haas, C. A.
author_sort Kleis, P.
collection PubMed
description BACKGROUND: Optogenetic tools allow precise manipulation of neuronal activity via genetically encoded light-sensitive proteins. Currently available optogenetic inhibitors are not suitable for prolonged use due to short-lasting photocurrents, tissue heating, and unintended changes in ion distributions, which may interfere with normal neuron physiology. To overcome these limitations, a novel potassium channel-based optogenetic silencer, named PACK, was recently developed. The PACK tool has two components: a photoactivated adenylyl cyclase from Beggiatoa (bPAC) and a cAMP-dependent potassium channel, SthK, which carries a large, long-lasting potassium current in mammalian cells. Previously, it has been shown that activating the PACK silencer with short light pulses led to a significant reduction of neuronal firing in various in vitro and acute in vivo settings. Here, we examined the viability of performing long-term studies in vivo by looking at the inhibitory action and side effects of PACK and its components in healthy and epileptic adult male mice. RESULTS: We targeted hippocampal cornu ammonis (CA1) pyramidal cells using a viral vector and enabled illumination of these neurons via an implanted optic fiber. Local field potential (LFP) recordings from CA1 of freely moving mice revealed significantly reduced neuronal activity during 50-min intermittent (0.1 Hz) illumination, especially in the gamma frequency range. Adversely, PACK expression in healthy mice induced chronic astrogliosis, dispersion of pyramidal cells, and generalized seizures. These side effects were independent of the light application and were also present in mice expressing bPAC without the potassium channel. Light activation of bPAC alone increased neuronal activity, presumably via enhanced cAMP signaling. Furthermore, we applied bPAC and PACK in the contralateral hippocampus of chronically epileptic mice following a unilateral injection of intrahippocampal kainate. Unexpectedly, the expression of bPAC in the contralateral CA1 area was sufficient to prevent the spread of spontaneous epileptiform activity from the seizure focus to the contralateral hippocampus. CONCLUSION: Our study highlights the PACK tool as a potent optogenetic inhibitor in vivo. However, further refinement of its light-sensitive domain is required to avoid unexpected physiological changes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12915-021-01210-1.
format Online
Article
Text
id pubmed-8760681
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87606812022-01-18 Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus Kleis, P. Paschen, E. Häussler, U. Bernal Sierra, Y. A. Haas, C. A. BMC Biol Research Article BACKGROUND: Optogenetic tools allow precise manipulation of neuronal activity via genetically encoded light-sensitive proteins. Currently available optogenetic inhibitors are not suitable for prolonged use due to short-lasting photocurrents, tissue heating, and unintended changes in ion distributions, which may interfere with normal neuron physiology. To overcome these limitations, a novel potassium channel-based optogenetic silencer, named PACK, was recently developed. The PACK tool has two components: a photoactivated adenylyl cyclase from Beggiatoa (bPAC) and a cAMP-dependent potassium channel, SthK, which carries a large, long-lasting potassium current in mammalian cells. Previously, it has been shown that activating the PACK silencer with short light pulses led to a significant reduction of neuronal firing in various in vitro and acute in vivo settings. Here, we examined the viability of performing long-term studies in vivo by looking at the inhibitory action and side effects of PACK and its components in healthy and epileptic adult male mice. RESULTS: We targeted hippocampal cornu ammonis (CA1) pyramidal cells using a viral vector and enabled illumination of these neurons via an implanted optic fiber. Local field potential (LFP) recordings from CA1 of freely moving mice revealed significantly reduced neuronal activity during 50-min intermittent (0.1 Hz) illumination, especially in the gamma frequency range. Adversely, PACK expression in healthy mice induced chronic astrogliosis, dispersion of pyramidal cells, and generalized seizures. These side effects were independent of the light application and were also present in mice expressing bPAC without the potassium channel. Light activation of bPAC alone increased neuronal activity, presumably via enhanced cAMP signaling. Furthermore, we applied bPAC and PACK in the contralateral hippocampus of chronically epileptic mice following a unilateral injection of intrahippocampal kainate. Unexpectedly, the expression of bPAC in the contralateral CA1 area was sufficient to prevent the spread of spontaneous epileptiform activity from the seizure focus to the contralateral hippocampus. CONCLUSION: Our study highlights the PACK tool as a potent optogenetic inhibitor in vivo. However, further refinement of its light-sensitive domain is required to avoid unexpected physiological changes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12915-021-01210-1. BioMed Central 2022-01-14 /pmc/articles/PMC8760681/ /pubmed/35031048 http://dx.doi.org/10.1186/s12915-021-01210-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Kleis, P.
Paschen, E.
Häussler, U.
Bernal Sierra, Y. A.
Haas, C. A.
Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus
title Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus
title_full Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus
title_fullStr Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus
title_full_unstemmed Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus
title_short Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus
title_sort long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760681/
https://www.ncbi.nlm.nih.gov/pubmed/35031048
http://dx.doi.org/10.1186/s12915-021-01210-1
work_keys_str_mv AT kleisp longterminvivoapplicationofapotassiumchannelbasedoptogeneticsilencerinthehealthyandepilepticmousehippocampus
AT paschene longterminvivoapplicationofapotassiumchannelbasedoptogeneticsilencerinthehealthyandepilepticmousehippocampus
AT haussleru longterminvivoapplicationofapotassiumchannelbasedoptogeneticsilencerinthehealthyandepilepticmousehippocampus
AT bernalsierraya longterminvivoapplicationofapotassiumchannelbasedoptogeneticsilencerinthehealthyandepilepticmousehippocampus
AT haasca longterminvivoapplicationofapotassiumchannelbasedoptogeneticsilencerinthehealthyandepilepticmousehippocampus